Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial

Open access

Abstract

Objective: This study aimed to assess the efficacy and safety of camrelizumab plus apatinib in patients with resectable hepatocellular carcinoma (HCC) as neoadjuvant therapy. Methods: Initially, 20 patients with HCC were screened and 18 patients with resectable HCC were enrolled in this open-label, single-arm, phase II clinical trial. Patients received three cycles of neoadjuvant therapy including three doses of camrelizumab concurrent with apatinib for 21 days followed by surgery. Four to 8 weeks after surgery, patients received eight cycles of adjuvant therapy with camrelizumab in combination with apatinib. Major pathological reactions (MPR), complete pathological reactions (pCR), objective response rate (ORR), relapse-free survival (RFS), and adverse events (AE) were assessed. In addition, cancer tissue and plasma samples were collected before and after treatment, and genetic differences between responding and non-responding lesions were compared by tumor immune microenvironment (TIME) analysis, circulating tumor DNA (ctDNA) analysis and proteomics analysis. Results: In 18 patients with HCC who completed neoadjuvant therapy, 3 (16.7%) and 6 (33.3%) patients with HCC reached ORR based on Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 and modified RECIST criteria, respectively. Of the 17 patients with HCC who received surgical resection, 3 (17.6%) patients with HCC reported MPR and 1 (5.9%) patient with HCC achieved pCR. The 1-year RFS rate of the enrolled patients was 53.85% (95% CI: 24.77% to 75.99%). Grade 3/4 AEs were reported in 3 (16.7%) of the 18 patients, with the most common AEs being rash (11.1%), hypertension (5.6%), drug-induced liver damage (5.6%), and neutropenia (5.6%) in the preoperative phase. The 289 NanoString panel RNA sequencing showed that TIME cell infiltration especially dendritic cells (DCs) infiltration was better in responding tumors than in non-responding tumors. Our results of ctDNA revealed a higher positive rate (100%) among patients with HCC with stage IIb–IIIa disease. When comparing patients with pCR/MPR and non-MPR, we observed more mutations in patients who achieved pCR/MPR at baseline (6 mutations vs 2.5 mutations, p=0.025). Patients who were ctDNA positive after adjuvant therapy presented a trend of shorter RFS than those who were ctDNA negative. Proteomic analysis suggested that abnormal glucose metabolism in patients with multifocal HCC might be related to different sensitivity of treatment in different lesions. Conclusion: Perioperative camrelizumab plus apatinib displays a promising efficacy and manageable toxicity in patients with resectable HCC. DCs infiltration might be a predictive marker of response to camrelizumab and apatinib as well as patients’ recurrence. ctDNA as a compose biomarker can predict pathological response and relapse. Abnormal glucose metabolism in patients with multifocal HCC may be related to different sensitivity of treatment in different lesions. Trial registration number: NCT04297202.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2022-004656

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study design. (A) Flowchart of enrolled patients. (B) Flowchart of therapeutic regimen. (C) Treatment was evaluated for the enrolled patients based on RECIST V.1.1 criteria and mRECIST criteria. (D) Measuring of AFP level change during perioperative period in patients with surgical resectable HCC. HCC, hepatocellular carcinoma; mRECIST, modified RECIST; RECIST, Response Evaluation Criteria in Solid Tumors.
Figure 1 Study design. (A) Flowchart of enrolled patients. (B) Flowchart of therapeutic regimen. (C) Treatment was evaluated for the enrolled patients based on RECIST V.1.1 criteria and mRECIST criteria. (D) Measuring of AFP level change during perioperative period in patients with surgical resectable HCC. HCC, hepatocellular carcinoma; mRECIST, modified RECIST; RECIST, Response Evaluation Criteria in Solid Tumors.CC BY · PubMed Central
Figure 2 Response to treatment in typical cases. (A) Patient 5; male; 70 years old; stage IIb; total five lesions, maximum diameter 32.6 mm; after neoadjuvant therapy, RECIST V.1.1 and mRECIST evaluation were PR; surgical pathology only showed two large lesions and were both pCR. (B) Patient 14; female; 53 years old; stage IIIa; tumor diameter 108.1 mm; after neoadjuvant therapy, RECIST V.1.1 evaluation was stable disease, mRECIST evaluation was PR; surgical pathology was MPR. (C) Patient 12; male; 55 years old; stage IIb; seven tumor nodules; the largest of which was 80 mm in diameter; after neoadjuvant therapy, five tumors were resected, among which S3–2 lesion was treated with pCR, S4–2 and S8 lesions with microwave. DFS is 293 days. (D) The relationship between tumor diameter and pathological response. *P<0.05. Arrows represent lesions.RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified RECIST;PR, partial response; pCR, pathological reactions;MPR, major pathological reactions; DFS, Disease Free Survival.
Figure 2 Response to treatment in typical cases. (A) Patient 5; male; 70 years old; stage IIb; total five lesions, maximum diameter 32.6 mm; after neoadjuvant therapy, RECIST V.1.1 and mRECIST evaluation were PR; surgical pathology only showed two large lesions and were both pCR. (B) Patient 14; female; 53 years old; stage IIIa; tumor diameter 108.1 mm; after neoadjuvant therapy, RECIST V.1.1 evaluation was stable disease, mRECIST evaluation was PR; surgical pathology was MPR. (C) Patient 12; male; 55 years old; stage IIb; seven tumor nodules; the largest of which was 80 mm in diameter; after neoadjuvant therapy, five tumors were resected, among which S3–2 lesion was treated with pCR, S4–2 and S8 lesions with microwave. DFS is 293 days. (D) The relationship between tumor diameter and pathological response. *P<0.05. Arrows represent lesions.RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified RECIST;PR, partial response; pCR, pathological reactions;MPR, major pathological reactions; DFS, Disease Free Survival.CC BY · PubMed Central
Figure 3 Comparison of expression of immune-related genes between responding and non-responding lesions. (A–B) Expression of immune-related genes per pretreatment sample of response and non-response groups. In the heatmap (A), red indicates an increased gene expression and blue indicates a decreased gene expression. (C–D) GO (C) and Kyoto Encyclopedia of Genes and Genomes (D) pathway analysis of the pretreatment samples. The count represents the number of genes in each pathway and dot size corresponds to ‘count’. GO, gene ontology.
Figure 3 Comparison of expression of immune-related genes between responding and non-responding lesions. (A–B) Expression of immune-related genes per pretreatment sample of response and non-response groups. In the heatmap (A), red indicates an increased gene expression and blue indicates a decreased gene expression. (C–D) GO (C) and Kyoto Encyclopedia of Genes and Genomes (D) pathway analysis of the pretreatment samples. The count represents the number of genes in each pathway and dot size corresponds to ‘count’. GO, gene ontology.CC BY · PubMed Central
Figure 4 Comparison of cell type scores between responding and non-responding lesions. (A–B) Different cell type scores in per pretreatment sample of response and non-response groups. Red indicates an increased cell type scores and blue indicates a decreased cell type scores. (C) The cell type scores of DCs between response and non-response groups. CTL, cytotoxic T lymphocyte; CYT, cytolytic activity; DC, dendritic cell; GEP, gene expression profiling; IFN, interferon; NK, natural killer; Teff, T-effector; TIL, tumor infiltrating lymphocytes.
Figure 4 Comparison of cell type scores between responding and non-responding lesions. (A–B) Different cell type scores in per pretreatment sample of response and non-response groups. Red indicates an increased cell type scores and blue indicates a decreased cell type scores. (C) The cell type scores of DCs between response and non-response groups. CTL, cytotoxic T lymphocyte; CYT, cytolytic activity; DC, dendritic cell; GEP, gene expression profiling; IFN, interferon; NK, natural killer; Teff, T-effector; TIL, tumor infiltrating lymphocytes.CC BY · PubMed Central
Figure 5 Pre-to-post-treatment changes of tumor immune microenvironment between responding and non-responding lesions. (A–B) Pre-to-post-treatment changes of immune-related genes expression according to response and non-response groups. In the heatmap (A), red indicates an increase and blue indicates a decrease. (C) Pre-to-post-treatment changes of cell type scores and immune signature scores according to response and non-response groups. Red indicates an increase and blue indicates a decrease. (D) Pre-to-post-treatment changes of IFN-γ signature scores between response and non-response groups. (E) Pre-to-post-treatment changes of DCs scores between response and non-response groups. CTL, cytotoxic T lymphocyte; CYT, cytolytic activity; DC, dendritic cell; GEP, gene expression profiling; IFN, interferon; NK, natural killer; Teff, T-effector; TIL, tumor infiltrating lymphocytes.
Figure 5 Pre-to-post-treatment changes of tumor immune microenvironment between responding and non-responding lesions. (A–B) Pre-to-post-treatment changes of immune-related genes expression according to response and non-response groups. In the heatmap (A), red indicates an increase and blue indicates a decrease. (C) Pre-to-post-treatment changes of cell type scores and immune signature scores according to response and non-response groups. Red indicates an increase and blue indicates a decrease. (D) Pre-to-post-treatment changes of IFN-γ signature scores between response and non-response groups. (E) Pre-to-post-treatment changes of DCs scores between response and non-response groups. CTL, cytotoxic T lymphocyte; CYT, cytolytic activity; DC, dendritic cell; GEP, gene expression profiling; IFN, interferon; NK, natural killer; Teff, T-effector; TIL, tumor infiltrating lymphocytes.CC BY · PubMed Central
Figure 6 Detection of ctDNA and its association with pathologic response. (A) Plot of ctDNA status for group MPR and non-MPR at T0 (pre-neoadjuvant), T1 (post-neoadjuvant), T2 (post surgery) and T3 (post-adjuvant therapy). Non-MPR, group of patients did not achieve pathologic response of MPR/pCR. (B) Mutational landscape of 12 samples at baseline (T0). (C) Comparison of positive rates from T0 to T3 between group of MPR/pCR and non-MPR. (D) Maximum variant allele frequency (mVAF) in group of non-MPR, MPR/pCR before and after neoadjuvant therapy and comparison of the change of mVAF. ctDNA, circulating tumor DNA; MPR, major pathological reactions; pCR, pathological reactions.
Figure 6 Detection of ctDNA and its association with pathologic response. (A) Plot of ctDNA status for group MPR and non-MPR at T0 (pre-neoadjuvant), T1 (post-neoadjuvant), T2 (post surgery) and T3 (post-adjuvant therapy). Non-MPR, group of patients did not achieve pathologic response of MPR/pCR. (B) Mutational landscape of 12 samples at baseline (T0). (C) Comparison of positive rates from T0 to T3 between group of MPR/pCR and non-MPR. (D) Maximum variant allele frequency (mVAF) in group of non-MPR, MPR/pCR before and after neoadjuvant therapy and comparison of the change of mVAF. ctDNA, circulating tumor DNA; MPR, major pathological reactions; pCR, pathological reactions.CC BY · PubMed Central
Figure 7 Change of tumor lesion and mVAF of ctDNA in Patient 14 (A–B) and 16 (C–D). Arrows represent lesions. mVAF, maximum variant allele frequency.
Figure 7 Change of tumor lesion and mVAF of ctDNA in Patient 14 (A–B) and 16 (C–D). Arrows represent lesions. mVAF, maximum variant allele frequency.CC BY · PubMed Central
Figure 8 The difference in proteomics between the responding and non-responding tumors. (A–B) Heatmap (A) and volcano map (B) of different proteins between responding and non-responding lesions. T indicates non-responding lesions and W indicates responding lesions. (C) Gene ontology analysis results of different proteins between responding and non-responding lesions. (D) Kyoto Encyclopedia of Genes and Genomes pathway analysis of different proteins between responding and non-responding lesions.
Figure 8 The difference in proteomics between the responding and non-responding tumors. (A–B) Heatmap (A) and volcano map (B) of different proteins between responding and non-responding lesions. T indicates non-responding lesions and W indicates responding lesions. (C) Gene ontology analysis results of different proteins between responding and non-responding lesions. (D) Kyoto Encyclopedia of Genes and Genomes pathway analysis of different proteins between responding and non-responding lesions.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 240

Metadata

Authors
Xia, Y., Tang, W., Qian, X., Li, X., Cheng, F., Wang, K., Zhang, F., Zhang, C., Li, D., Song, J., Zhang, H., Zhao, J., Yao, A., Wu, X., Wu, C., Ji, G., Liu, X., Zhu, F., Qin, L., Xiao, X., Deng, Z., Kong, X., Li, S., Yu, Y., Xi, W., Deng, W., Qi, C., Liu, H., Pu, L., Wang, P., & Wang, X.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China
  • Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
  • Jiangsu Province Hospital (CN)
  • Simcere Pharmaceutical (China) (CN)
Corresponding author
  • Xia, Yongxiang
  • Pu, Liyong
  • Wang, Ping
  • Wang, Xuehao
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2022-04
Volume
10
Issue
4
Pages
e004656
ISSN
2051-1426 (ISSN-L)
OpenAlex
W4224325284
Cited by
228
References
68
Citations by year
2026: 49 · 2025: 61 · 2024: 60 · 2023: 47 · 2022: 11
FWCI
26.67
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Natural Science Foundation of China (82070676)
  • National Natural Science Key Foundation of China (31930020)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
camrelizumab, apatinib, hepatocellular carcinoma, neoadjuvant therapy, adjuvant therapy, perioperative immunotherapy, resectable liver cancer, tumor immune microenvironment, dendritic cell infiltration, circulating tumor DNA, proteomics, predictive biomarkers, relapse-free survival
MeSH terms
Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Neoplasm Recurrence, Local, Pyridines, Proteomics, Tumor Microenvironment, Perioperative Period, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. https://app.cochat.ai/papers/10.1136/jitc-2022-004656
The paper
Xia, Y., Tang, W., Qian, X., Li, X., Cheng, F., Wang, K., Zhang, F., Zhang, C., Li, D., Song, J., Zhang, H., Zhao, J., Yao, A., Wu, X., Wu, C., Ji, G., Liu, X., Zhu, F., Qin, L., . . . Wang, X. (2022). Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-004656

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.